AbbVie (ABBV) Dividend Analyzer Analysis
The AbbVie dividend has been paid continuously since 1924 and increased for 44 consecutive years; qualifying the company as a Dividend Aristocrat. (Technically AbbVie has only existed since 2013. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs (AbbVie was spun-off by Abbott) dividend record and is considered a Dividend Aristocrat.
Current Dividend: $2.84
Dividend Yield: 3.0%
Cash Dividend Payout Ratio: 47%
Market Capitalization: 153 B
Enterprise Value: 179 B
Industry: Drug Manufacturers – Major
AbbVie is a global, research-based biopharmaceutical company formed in 2013 (spin-off from Abbott Laboratories). The company’s mission is to use its expertise, dedicated people, and unique approach to innovation to develop and market advanced therapies that address some of the world’s greatest health challenges.
The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie has 23 billion in annual sales, employs more than 28,000 people worldwide, and markets medicines in more than 170 countries.
Source: AbbVie Company Website
Dividend Analyzer Checklist
(updated November 2017)
Dividend Safety Score (16/33 points)
Dividend Payout Ratio (ttm): 59%
Cash Dividend Payout Ratio (ttm): 59% (7/12 points)
Dividend Per Share (ttm): $2.42
Cash From Operations (CFO) Per Share (ttm): $4.39
Free Cash Flow (FCF) Per Share (ttm): $4.11
Net Financial Debt: $30032 M
Total Assets: $66994 M
Net Financial Debt / Total Assets: 44% (3/12 points)
Net Financial Debt to EBITDA (ttm): 341%
Piotroski Score (1-9) (TTM): (6/9 points)
Profitability Score (16/33 points)
Operating Earnings Yield (ttm): 6.9% (8/15 points)
Net Income (ttm): $6615 M
Gross Profit (ttm): $20507 M
Total Assets: $65664 M
Gross Profitability Ratio = GP / Total Assets: 31% (8/18 points)
Cash Return On Invested Capital (CROIC)(tttm): 16%
Return on Invested Capital (ROIC): 15%
Valuation Score (14/34 points)
Free Cash Flow Yield (ttm): 4.5% (9/17 points)
EV to EBIT (ttm): 18.4
EV to EBITDA (ttm): 15.8 (5/17 points)
Price to Sales Ratio (ttm): 5.6
Price to Book Value (ttm): 24.4
Price to Earnings Ratio (P/E) (ttm): 23
TOTAL POINTS – (46/100) (50 is an average score)
Earnings Report: 10/27/17
Stay Updated All the Time!
Dividend Safety, Profitability, and Valuation Scores for 300+ Dividend Stocks Each Month.
Fundamental Quantitative Analysis to Find the "Hidden Gems".
Six Dividend Portfolios (Stocks & ETFs).
(updated November 2017)
AbbVie is ranked #210 (out of 377) overall and #22 (out of 31) in the Healthcare Sector by the Dividend Analyzer.
Type of Investor / Recommendation
Large Diversified Dividend Portfolios / Can Be Considered
Looking For Exposure to Healthcare Sector / AVOID
Deep Value Investors / AVOID
Portfolio Position Disclosures:
DVB Foundation Portfolio: None
DVB Dividend Growth: None
DVB High Income: None
Arbor Asset Allocation Model Portfolio (AAAMP): None
Dividend Investing Without Emotional Bias
Get All 3 Dividend Value Builder Services for 1 Low Price: $99/year (save 33% over purchasing separately).
Dividend Analyzer, Treasure Trove Twelve, & Dividend Portfolios Newsletters
Free 7-Day Trial. You take NO risk. Start today!